ArticleCellular & molecular biology letters2026
GPNMB-ECD drives acquired resistance to osimertinib in NSCLC via inducing tumor cell cytoskeletal reorganization.
Article in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAcquired resistance constitutes a major obstacle to the efficacy of osimertinib therapy in nonsmall-cell lung cancer (NSCLC), yet its underlying mechanisms remain incompletely understood. While the soluble extracellular domain of GPNMB (GPNMB-ECD) is recognized as a driver of tumor progression, its involvement in acquired resistance to osimertinib remains unknown. PURPOSE: This study aimed to investigate the role of GPNMB-ECD in acquired osimertinib resistance in NSCLC.
methodsThe expression dynamics of GPNMB in osimertinib-sensitive (OS) and osimertinib-resistant (OR) NSCLC tissues and cell lines were profiled using single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq, respectively. Full-length GPNMB and GPNMB-ECD levels in tumor tissues and patient plasma were assessed by immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA). In vitro, the impact of GPNMB-ECD on osimertinib sensitivity was evaluated using CCK-8, colony formation, flow cytometry, and transwell assays. Correspondingly, in vivo effects were investigated in nude mouse models of subcutaneous and pulmonary metastasis. The underlying mechanisms were explored through co-immunoprecipitation (Co-IP), immunofluorescence, and transmission electron microscopy (TEM). Finally, the therapeutic efficacy of the anti-GPNMB-ECD antibody was evaluated in humanized patient-derived xenograft (huPDX) models.
resultsTumor cells exhibited elevated GPNMB expression in OR tissues compared with OS controls and emerged as the primary source of GPNMB-ECD within the OR TME. Plasma levels of GPNMB-ECD were substantially higher in patients with OR NSCLC compared with patients with OS NSCLC, suggesting this marker as a potential indicator of acquired resistance and poor prognosis. Functional studies confirmed that GPNMB-ECD promotes osimertinib resistance both in vitro and in vivo. Mechanistically, GPNMB-ECD engages syndecan-4 (SDC4) on tumor cells, triggering SDC4 phosphorylation, F-actin reorganization, and Yes-associated protein (YAP) nuclear translocation, thereby upregulating pro-tumorigenic genes and reducing osimertinib sensitivity. Crucially, anti-GPNMB-ECD antibodies restored osimertinib sensitivity in huPDX models established from human NSCLC tumors.
conclusionsOur findings define GPNMB-ECD-driven resistance as a novel paradigm in NSCLC and identify a viable precision therapeutic strategy to overcome it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.